FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo

British Journal of Dermatology

Volumn 160, Issue 3, 2009, Pages 546-551

  Hafner, C ^a   Stoehr, R ^b   Van Oers, J M M ^c   Zwarthoff, E C ^c   Hofstaedter, F ^a   Landthaler, M ^a   Hartmann, A ^b   Vogt, T ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

FGFR3; PIK3CA; Seborrhoeic keratosis; Senile lentigo; Skin; Solar lentigo

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; AGED; ALLELE; ARTICLE; ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; HUMAN; LENTIGO; MALE; MUTATION; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUVA; SCREENING; SEQUENCE ANALYSIS; SOLAR LENTIGO;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LENTIGO; MALE; MIDDLE AGED; MUTATION; PHOTOSENSITIVITY DISORDERS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SKIN AGING;

EID: 60449111332     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08963.x     Document Type: Article

References (27)

1. Barnhill LB, Llewellyn K. Benign melanocytic neoplasms. In : Dermatology (Bolognia JL, Jorizzo JL, Rapini RP, eds Vol. 2. London : Mosby, 2003 1760.
2. Ackerman AB, Ragaz A. The Lives of Lesions. New York : Masson Publishing USA, 1984.
3. Hattori H, Kawashima M, Ichikawa Y et al. The epidermal stem cell factor is over-expressed in lentigo senilis: implication for the mechanism of hyperpigmentation. J Invest Dermatol 2004 122 : 1256 65.
4. Aoki H, Moro O, Tagami H et al. Gene expression profiling analysis of solar lentigo in relation to immunohistochemical characteristics. Br J Dermatol 2007 156 : 1214 23.
5. Logie A, Dunois-Larde C, Rosty C et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 2005 14 : 1153 60.
6. Hafner C, Hartmann A, van Oers JM et al. FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization. Mod Pathol 2007 20 : 895 903.
7. Hafner C, van Oers JM, Hartmann A et al. High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol 2006 126 : 2404 7.
8. Hafner C, Hartmann A, Real FX et al. Spectrum of FGFR3 mutations in multiple intraindividual seborrheic keratoses. J Invest Dermatol 2007 127 : 1883 5.
9. Hafner C, Lopez-Knowles E, Luis NM et al. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci USA 2007 104 : 13450 4.
10. Lassacher A, Worda M, Kaddu S et al. T1799A BRAF mutation is common in PUVA lentigines. J Invest Dermatol 2006 126 : 1915 17.
11. Hafner C, van Oers JM, Vogt T et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 2006 116 : 2201 7.
12. van Oers JM, Lurkin I, van Exsel AJ et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005 11 : 7743 8.
13. Lopez-Knowles E, Hernandez S, Malats N et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006 66 : 7401 4.
14. Stoehr R, Brinkmann A, Filbeck T et al. No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract. Oncol Rep 2004 11 : 137 41.
15. Naski MC, Wang Q, Xu J et al. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 1996 13 : 233 7.
16. Wilkie AO. Craniosynostosis: genes and mechanisms. Hum Mol Genet 1997 6 : 1647 56.
17. Vajo Z, Francomano CA, Wilkin DJ. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 2000 21 : 23 39.
18. Monsonego-Ornan E, Adar R, Feferman T et al. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol 2000 20 : 516 22.
19. Cho JY, Guo C, Torello M et al. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci USA 2004 101 : 609 14.
20. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006 94 : 455 9.
21. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 2007 104 : 5569 74.
22. Bader AG, Kang S, Zhao L et al. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005 5 : 921 9.
23. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006 103 : 1475 9.
24. Thomas NE. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 2006 16 : 97 103.
25. Yeatman JM, Kilkenny M, Marks R. The prevalence of seborrhoeic keratoses in an Australian population: does exposure to sunlight play a part in their frequency? Br J Dermatol 1997 137 : 411 14.
26. Collin B, Taylor IB, Wilkie AO et al. Fibroblast growth factor receptor 3 (FGFR3) mutation in a verrucous epidermal naevus associated with mild facial dysmorphism. Br J Dermatol 2007 156 : 1353 6.
27. Andersen WK, Labadie RR, Bhawan J. Histopathology of solar lentigines of the face: a quantitative study. J Am Acad Dermatol 1997 36 : 444 7.